The European Medicines Agency will hold its first ever public hearing on the safety of marketed medicines on Sept. 26 to review the use of valproate-containing medicines in the treatment of women and girls who are pregnant or of childbearing age.
The public hearing, to be held by the EMA’s Pharmacovigilance Risk Assessment Committee, will mark the first time that EU citizens will be given a voice
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?